Your Search Results

Left main complications - Part 2

21 May 2026 – From EuroPCR 2026

This session covers intricate complications involving the left main coronary artery (LMCA), highlighting cases of catheter-induced dissections, challenges in chronic total occlusion (CTO) PCI, and rare scenarios such as stent entrapment and complex re-interventions. Emphasis is placed on the critical utility of intravascular ultrasound (IVUS) and...

Novel indications for DCB

21 May 2026 – From EuroPCR 2026

This session reviews emerging clinical applications for drug-coated balloons (DCB) beyond traditional indications. It covers outcomes in venous stenosis, aorto-ostial lesions, and coronary bifurcation disease, comparing DCB strategies with drug-eluting stents and highlighting recent clinical trial findings.

Primary PCI dilemmas: when imaging saves the day

21 May 2026 – From EuroPCR 2026

This session highlights the pivotal role of imaging in resolving dilemmas during primary percutaneous coronary intervention (PCI). It presents complex cases illustrating challenges such as coronary compression, thrombus burden in large vessels, and culprit lesion identification, including the use of high-definition intravascular ultrasound (HD-IVUS) to reclassify...

Optimising TAVI care pathways

21 May 2026 – From EuroPCR 2026

This session examines innovations in TAVI care pathways aimed at improving patient outcomes and healthcare efficiency. Topics include large-scale transatlantic data on day-case TAVI, standardized ECG conduction algorithms reducing hospital stay, nurse-led structured pathways, feasibility of very early discharge, and urgent outpatient TAVI for severe aortic...

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

05 Sep 2023

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Author

Alessandro Sticchi

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

Evidence base: current data on TAVI durability and long-term outcomes

22 Jul 2026

This article reviews the current evidence on TAVI durability, focusing on long-term outcomes, device-specific considerations, and the implications for lifetime management strategies.

Author

Tanja Rudolph

Author

Georges El Hachem

Evidence base: current data on durability

SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk

07 Nov 2021

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...